A recent meta-analysis of all GLP-1 RAs (including OW and once-daily versions) [22] assessing outcomes across CVOTs found that GLP-1 RAs reduced 3-point MACE by 14%, including a 10% reduction in MI risk and a 17% reduction in stroke risk. Here, GLP1R is linked to stroke disorder.